Paper2522751
Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Erlich KS and 7 others. Ann Intern Med, 1989. Cited by 98 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Papers, record 2522751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2522751
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acquired Immunodeficiency Syndrome | Major topic |
| Antiviral Agents | Major topic |
| Herpes Simplex | Major topic |
| Organophosphorus Compounds | Major topic |
| Phosphonoacetic Acid | Major topic |
| Acyclovir | |
| Adult | |
| Drug Resistance, Microbial | |
| Foscarnet | |
| Humans | |
| Infusions, Intravenous | |
| Male | |
| Microbial Sensitivity Tests |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 5-T32-AI07234 | NIAID NIH HHS | United States | T32AI007234 | PubMed and NIH |
Source NIH RePORTER
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 98 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40557131 | Management of Resistant Herpetic Whitlow: A Case of Recurrent Herpetic Whitlow Resistant to Standard Therapy. | Case Rep Dermatol | 2025 | https://conductscience.org/library/papers/40557131 | PubMed |
| 21078929 | Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21078929 | PubMed |
| 18750674 | Dermatology: cutaneous manifestations of human immunodeficiency virus infection. | West J Med | 1989 | https://conductscience.org/library/papers/18750674 | PubMed |
| 15673740 | Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15673740 | PubMed |
| 12669211 | [Acyclovir-resistant herpes exulcerans et persistens. Type II]. | Hautarzt | 2003 | https://conductscience.org/library/papers/12669211 | PubMed |
| 12525428 | Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. | Clin Microbiol Rev | 2003 | https://conductscience.org/library/papers/12525428 | PubMed |
| 10952566 | Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10952566 | PubMed |
| 10898688 | A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10898688 | PubMed |
| 10602719 | Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10602719 | PubMed |
| 9797252 | Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9797252 | PubMed |
| 9421709 | What clinicians need to know about antiviral drugs and viral resistance. | Infect Dis Clin North Am | 1997 | https://conductscience.org/library/papers/9421709 | PubMed |
| 9010648 | Drug treatment of HIV-related opportunistic infections. | Drugs | 1997 | https://conductscience.org/library/papers/9010648 | PubMed |
| 8794364 | Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. | J Virol | 1996 | https://conductscience.org/library/papers/8794364 | PubMed |
| 8540707 | Foscarnet alters antidiuretic hormone-mediated transport. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/8540707 | PubMed |
| 7553576 | Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. | Clin Microbiol Rev | 1995 | https://conductscience.org/library/papers/7553576 | PubMed |
| 7527325 | Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. | Drugs | 1994 | https://conductscience.org/library/papers/7527325 | PubMed |
| 7512902 | Genital herpes. A guide to pharmacological therapy. | Drugs | 1994 | https://conductscience.org/library/papers/7512902 | PubMed |
| 2069375 | Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. | Antimicrob Agents Chemother | 1991 | https://conductscience.org/library/papers/2069375 | PubMed |
| 1828096 | Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet. | Klin Wochenschr | 1991 | https://conductscience.org/library/papers/1828096 | PubMed |
| 1576586 | Antiviral therapy: current concepts and practices. | Clin Microbiol Rev | 1992 | https://conductscience.org/library/papers/1576586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2522751
GET https://conductscience.org/api/papers/v1/2522751/authors